Glossary
Explore the full definitions and explanation of the goals
interactions
How patient groups interact with drug regulators
Working with regulatory bodies
Patient organisations engage directly with national medicines regulators and health authorities, submitting contributions, proposals and formal requests. This work establishes them as recognised interlocutors in regulatory processes, and many report actively seeking closer, more formalised relationships with these bodies.
Participate in Health Technology Assessment (HTA) and reimbursement reviews
Groups take part in health technology assessment and reimbursement evaluations, responding to consultations and preparing submissions that accompany reimbursement applications. By feeding into the bodies that appraise new treatments, they help ensure the patient perspective shapes which therapies are ultimately funded. This is the single most frequently reported form of engagement.
Contribute to Marketing Authorisation submissions
Organisations provide input into marketing-authorisation processes for new and orphan medicines, offering opinions to regulators and supporting applications for approval. Their contributions range from scientific-advice committees and fast-track designations to formal position statements backing a product's introduction.
Involvement with clinical guideline-setting bodies
Patient representatives sit on guideline and expert committees, helping to shape clinical standards. Involvement is typically through formal membership of the committees that develop national clinical guidelines and quality standards.
Attend/facilitate meetings with policymakers/regulators
Groups actively request and attend meetings, roundtables and consultative sessions with regulators, ministries and health authorities. Whether convened by invitation or sought proactively, these encounters give patients a direct channel to decision-makers.
With other healthcare advocates
Much engagement happens collectively, through umbrella and federation bodies that advocate on members' behalf. Joint position statements and shared representation amplify the voices of smaller organisations in reimbursement and regulatory forums.
Participate in public hearings and consultations
Groups submit formal responses to public consultations and take part in parliamentary hearings, forums and working groups. They use these open processes to convey the patient perspective directly to decision-makers.
Contribute to the drafting of public health legislation
Groups actively help draft and refine health laws, commenting on legislative proposals and, in some cases, sponsoring bills. They contribute technical input and amendments across a range of access, equity and medicines legislation.
Engage in price-review board negotiations
Groups participate directly in the bodies that set prices and reimbursement terms — completing questionnaires, sitting on advisory councils and joining negotiation roundtables. Their input brings patient priorities into otherwise technical pricing decisions.
Use patient insights to inform decisions
Organisations systematically gather and convey patient views to inform regulatory, reimbursement and policy decisions — through advisory councils, questionnaires, nominated committee members and formal submissions. This ensures decisions reflect real patient priorities.
Provide Real-World Evidence (RWE) to regulatory agencies
Groups generate and submit structured real-world evidence and patient-reported outcomes to inform HTA and reimbursement, translating lived experience into policy-relevant data. This articulates treatment burden, unmet needs and value beyond clinical endpoints.
Leverage patient stories and lived-experience narratives
Advocates bring patient and caregiver stories into appraisals, consultations and media to demonstrate the human impact of treatment and access decisions. Lived-experience submissions give qualitative weight to reimbursement cases.
Translate evidence and insights into policy input
Groups convert technical, clinical and scientific evidence into structured recommendations and position papers for decision-makers. Through scientific committees, technical briefs and formal submissions, they recommend which medicines and supplies should be incorporated into health systems.
Participate in developing clinical guidelines
Organisations contribute to clinical guideline and care-pathway development through technical working groups and committees. Their involvement helps ensure guidelines reflect patient needs and the realities of everyday care.
Collaborate on clinical trial design
Groups advise on trial design and endpoints, sitting on scientific advisory councils and working with regulators and sponsors. Their input covers issues such as eligibility, trial burden and improving studies for both sponsors and patients.
Ensure representation within governmental advisory bodies
Patient organisations secure formal seats on government advisory boards, committees and working groups. This embedded representation gives patients standing in ongoing health governance.
Working effectively within multi-stakeholder networks
Groups operate within broad networks linking patients, clinicians, industry, regulators and umbrella bodies. Collaboration across these platforms strengthens their collective influence.
Maintain formal status as public interest or charitable entity
Organisations establish and maintain formal legal standing — public-interest designation, charitable or non-profit registration, or listing on official interest-group registers — to legitimise their advocacy. This status underpins their recognition as social partners to the state.